Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors.

[1]  A. Zlotnick,et al.  The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine. , 2020, Biomaterials science.

[2]  N. Steinmetz,et al.  A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models , 2020, Advanced functional materials.

[3]  J. Rehwinkel,et al.  RIG-I-like receptors: their regulation and roles in RNA sensing , 2020, Nature Reviews Immunology.

[4]  N. Steinmetz,et al.  The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus‐Like Particles , 2020, Advanced functional materials.

[5]  Frank A. Veliz,et al.  Endosomal toll‐like receptors play a key role in activation of primary human monocytes by cowpea mosaic virus , 2019, Immunology.

[6]  N. Steinmetz,et al.  Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties , 2019, Journal of Virology.

[7]  K. Hefferon,et al.  Future of cancer immunotherapy using plant virus-based nanoparticles , 2019, Future science OA.

[8]  Janine K. Tom,et al.  Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune Responses , 2019, ACS central science.

[9]  H. Cai,et al.  Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis , 2019, Advanced science.

[10]  E. Allémann,et al.  Development of resiquimod‐loaded modified PLA‐based nanoparticles for cancer immunotherapy: A kinetic study , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  M. Vogel,et al.  Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine , 2019, Front. Immunol..

[12]  N. Steinmetz,et al.  Cowpea Mosaic Virus Promotes Anti‐Tumor Activity and Immune Memory in a Mouse Ovarian Tumor Model , 2019, Advanced therapeutics.

[13]  M. Vogel,et al.  Vaccination with nanoparticles combined with micro-adjuvants protects against cancer , 2019, Journal of Immunotherapy for Cancer.

[14]  M. Merad,et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.

[15]  M. Neek,et al.  Protein-based nanoparticles in cancer vaccine development. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[16]  Vanessa M. Hubbard-Lucey,et al.  Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors , 2018, Nature Reviews Drug Discovery.

[17]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[18]  R. Coffman,et al.  SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. , 2018, Cancer discovery.

[19]  B. Damania,et al.  cGAS and STING: At the intersection of DNA and RNA virus-sensing networks , 2018, PLoS pathogens.

[20]  L. Boon,et al.  Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment , 2018, Cancer Immunology Research.

[21]  H. Kaur,et al.  An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia , 2018, Front. Microbiol..

[22]  N. Steinmetz,et al.  In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. , 2018, Molecular pharmaceutics.

[23]  L. Galluzzi,et al.  Oncogene-induced senescence and tumour control in complex biological systems , 2018, Cell Death & Differentiation.

[24]  D. Czerwinski,et al.  Eradication of spontaneous malignancy by local immunotherapy , 2018, Science Translational Medicine.

[25]  E. Allémann,et al.  Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation. , 2018, International journal of pharmaceutics.

[26]  J. Tavernier,et al.  Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. , 2018, Cancer research.

[27]  P. Savard,et al.  Activation of innate immunity in primary human cells using a plant virus derived nanoparticle TLR7/8 agonist. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[28]  N. Steinmetz,et al.  Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response. , 2017, Nano letters.

[29]  F. Marincola,et al.  Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration , 2017, Clinical Cancer Research.

[30]  M. Bachmann,et al.  Harnessing Nanoparticles for Immunomodulation and Vaccines , 2017, Vaccines.

[31]  James R. Swartz,et al.  Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery , 2017, Bioengineering & translational medicine.

[32]  A. Salazar,et al.  Combining In Situ Vaccination with Immune Checkpoint Blockade Induces Long-Term Regression of Lymphoma Tumors , 2016 .

[33]  R. Twyman,et al.  Virus-based nanoparticles as platform technologies for modern vaccines. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[34]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[35]  I. Abraham,et al.  Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials , 2016, Cancer medicine.

[36]  E. Wherry,et al.  Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling , 2016, Cell.

[37]  P. Barnes,et al.  Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD , 2016, European Respiratory Journal.

[38]  P. Hertzog,et al.  Antitumour actions of interferons: implications for cancer therapy , 2016, Nature Reviews Cancer.

[39]  P. Savard,et al.  Potentiating Cancer Immunotherapy Using Papaya Mosaic Virus-Derived Nanoparticles. , 2016, Nano letters.

[40]  S. Soefje,et al.  Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[41]  J. Brody,et al.  In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf , 2015, Molecular oncology.

[42]  P. Lizotte,et al.  In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer , 2015, Nature nanotechnology.

[43]  D. Leclerc,et al.  Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants , 2015, Vaccines.

[44]  K. Odunsi,et al.  Non-redundant Requirement for CXCR3 Signaling during Tumoricidal T Cell Trafficking across Tumor Vascular Checkpoints , 2015, Nature Communications.

[45]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[46]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[47]  J. Mauer,et al.  Versatile functions for IL-6 in metabolism and cancer. , 2015, Trends in immunology.

[48]  R. Fan,et al.  Cancer Immunotherapy and Next-Generation Clinical Immune Assessment , 2014, Front. Oncol..

[49]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[50]  P. Savard,et al.  This information is current as Infection Listeria Monocytogenes Protection from Mediated − T Cell + Enhances CD 8 Nanoparticle Adjuvant Sensing by TLR 7 , 2013 .

[51]  Kui Li,et al.  Toll-Like Receptors in Antiviral Innate Immunity , 2013, Journal of Molecular Biology.

[52]  C. Hofmann,et al.  Interferon-α suppresses cAMP to disarm human regulatory T cells. , 2013, Cancer research.

[53]  N. Steinmetz,et al.  Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. , 2013, Molecular pharmaceutics.

[54]  T. Gajewski,et al.  Innate immune sensing of cancer: clues from an identified role for type I IFNs , 2012, Cancer Immunology, Immunotherapy.

[55]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[56]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[57]  Katelyn T. Byrne,et al.  New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma , 2011, Oncotarget.

[58]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[59]  B. Reizis,et al.  Plasmacytoid dendritic cells: recent progress and open questions. , 2011, Annual review of immunology.

[60]  T. Okazaki,et al.  IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity , 2011, The Journal of Immunology.

[61]  Z. Su,et al.  Particle size affects the cellular response in macrophages. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[62]  S. Akira,et al.  Immunological basis of M13 phage vaccine: Regulation under MyD88 and TLR9 signaling. , 2010, Biochemical and biophysical research communications.

[63]  Chris S. Rae,et al.  Interaction of Cowpea Mosaic Virus (CPMV) Nanoparticles with Antigen Presenting Cells In Vitro and In Vivo , 2009, PloS one.

[64]  G. Lomonossoff,et al.  Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. , 2009, Virology.

[65]  Michael Dougan,et al.  Immune therapy for cancer. , 2009, Annual review of immunology.

[66]  A. Cerwenka,et al.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.

[67]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[68]  Arthur M. Krieg,et al.  Toll-like receptor 9 (TLR9) agonists in the treatment of cancer , 2008, Oncogene.

[69]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[70]  Carl Nathan,et al.  Neutrophils and immunity: challenges and opportunities , 2006, Nature Reviews Immunology.

[71]  M. Kinouchi,et al.  Selective infiltration of CCR5+CXCR3+ T lymphocytes in human colorectal carcinoma , 2005, International journal of cancer.

[72]  C. Keller-Peck,et al.  Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. , 2005, Cancer research.

[73]  T. Compton,et al.  Innate Sensing of Viruses by Toll-Like Receptors , 2004, Journal of Virology.

[74]  Shizuo Akira,et al.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.

[75]  I. Kerr,et al.  Differential Responses to IFN-α Subtypes in Human T Cells and Dendritic Cells 12 , 2003, The Journal of Immunology.

[76]  F. Belardelli,et al.  Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-α and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response1 , 2003, The Journal of Immunology.

[77]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[78]  R. Leurs,et al.  Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). , 1999, The Journal of investigative dermatology.

[79]  A. Boutten,et al.  Oncostatin M production and regulation by human polymorphonuclear neutrophils. , 1999, Blood.

[80]  J. Sprent,et al.  Type I Interferon-mediated Stimulation of T Cells by CpG DNA , 1998, Journal of Experimental Medicine.

[81]  J. Ravetch,et al.  Biochemical characterization of a gamma interferon-inducible cytokine (IP-10) , 1987, The Journal of experimental medicine.

[82]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. , 2018, Nature biomedical engineering.

[83]  R. Jia,et al.  The effect of antigen size on the immunogenicity of antigen presenting cell targeted DNA vaccine. , 2012, International immunopharmacology.

[84]  S. Akira,et al.  Toll-Like receptors (TLRs) and their ligands. , 2008, Handbook of experimental pharmacology.

[85]  F. Belardelli,et al.  Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. , 2003, Journal of immunology.